

#### **Supplemental Figure 1:**




# S. aureus colonization status of AD patients on systemic immunomodulatory treatment and burden of S. aureus skin colonization in $AD_{control}$ patients on systemic immunomodulatory therapy

Subjects on systemic immunomodulatory treatment for management of AD (n = 22) in the total study cohort were grouped according to *S.aureus* skin colonization status (A). The number of patients is indicated on the x-axis and colonization status is shown on the y-axis. There was no significant correlation between colonization status systemic immunomodulatory treatment as assessed using the chi-squared test. (p value = 0.08). Colonized and on systemic immunomodulation: n = 10. Not colonized and on systemic immunomodulation: n = 12

Subjects on systemic immunomodulatory therapy within the  $AD_{control}$  cohort (n = 21) were grouped according to their burden of *S. aureus* skin colonization: negative (n=12), low (n=5) and high (n=4), to determine if thosewith high colonization represented therapeutic non-responders (B). The burden of *S. aureus* colonization is indicated on the x-axis and EASI score is indicated on the y-axis. There was no correlation between EASI score and the burden of *S. aureus* skin colonization using the t-test of Spearman correlation in  $AD_{control}$  subjects on systemic immunomodulatory therapy (p value = 0.63).




#### Supplemental Figure 2: Gating for circulating T cell populations



### Supplemental Figure 3: Gating for CLA<sup>+/-</sup> *S. aureus* antigen-specific memory responses

3



#### Supplemental Figure 4: Gating for total *S. aureus* antigen-specific memory responses

#### Supplemental Data 5: MIATA / MIANKA Checklist

#	Required	If available	Optional	MIANKA & MIATA Sub-Modules
	Module 1	- Sample		
	Module 1	A - Donor		
1.1	~			Essential donor info
	Module 1	B Source		
1.2	~			Source of cell material
1.3	~		_	Collection methodology
1.4		~		anti-coagulant, if available
1.5		~		Transportation/storage conditions for unprocessed samples, if available
1.6	~		_	Cell processing methodology
1.7				Median time and ranges from sample collection until end of cell processing, if available
1.8				Cut-offs, if used
	Module 1C - Cryopreservation and Storage			
1.9	~			Fresh or cryopreserved
		-		If cryopreserved
1.10		-		devices used
1.11		4		freezing process
1.12			-	medium used for freezing
1.13			-	Median time and temperature for each transportation and storage step, if available
1.14				Cut-offs, if used
		D - Cell Cou	nting	
1.15	~		1	Median cell yield and viability (where available)
1.16			-	before freezing
1.17			-	after thawing
1.18			-	after overnight resting
1.19				Cut-offs, if used
1.20	~			Cell counting methodology
1.21				Optional: Additional assessments

#### Module 2 - Assay Module 2A - Medium/serum 2.1 ~ Medium/(serum) details 2.2 ~ Pretesting info Module 2B - Assay 2.3 Treatment procedures of cells prior to assay, if applicable 2.4 2 Sufficient assay details Module 2C - Controls 2.5 ~ Internal assay controls 2.6 Acceptance criteria, if available 2.7 External reference samples, if used 2.8 Assay acceptance criteria, if available Module 3 - Data Acquisition Module 3A - Equipment and software 3.1 ~ Equipment and software version 3.2 Basic equipment settings, if available Module 3B - Acquisition Strategy and Gating 3.3 Detailed gating strategy or strategy for establishing spot detection parameters ~ 3.4 ~ Representative data set 3.5 Mean, median, ranges of event counts for relevant populations, if available 3.6 Optional: Unusual strategies explained 3.7 Optional: Review of raw data Module 4 - Results Module 4A - Raw data 4.1 Background and ag-specific reactivity levels, if available 4.2 Cut-off specifications and # of tests OOS, if available 4.3 ~ Accessibility of raw data addressed? Module 4B - Response deterr ation 4.4 ~ Definition of positive reactivity (above background) including tests applied 4.5 Parameters, software and version used for response determination, if applicable 4.6 ~ Response definition predefined or post-hoc? 4.7 Definition of response induced by treatment, if applicable 4.8 Any data excluded and why, if applicable? 4.9 Optional: Why test was used Module 5 Module 5A - General Lab Operation 5.1 Guidance of lab operations ~ Laboratory accreditions and certifications, if available 5.2 ~ Optional: Details on audits 5.3 Module 5B - Standardization 5.4 ~ Status of protocols Module 5C - Qualification/Validation 5.5 ~ Status of assays 5.6 Optional: Specific performance criteria

## Supplemental Data 6: Link to statistical coding

https://github.com/DanDempsey/AD\_Study\_Code